HER2 positive breast cancer
RecruitingComparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer
Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer
- Disease:HER2 positive breast cancer
- Substances:CapecitabineTrastuzumab+2
Austria- Participants:18–64 years · 65+ years
- Substances:Capecitabine














